Hematological Disorders News

Global Hematological Disorders Market 2017 - Regulatory and Reimbursement Policy Shifts Favor First-in-Class ... - GlobeNewswire (press release)



Global Hematological Disorders Market 2017 - Regulatory and Reimbursement Policy Shifts Favor First-in-Class ... 
GlobeNewswire (press release)
Hematological disorders market is small and represents a significant investment opportunity. Due to few treatment options, many patients have a poor quality of life and poor prognosis, especially those with more severe disease states. Severe disease ...

and more » 


Can the organ of life save lives? - The Jerusalem Post



The Jerusalem Post
 
Can the organ of life save lives? 
The Jerusalem Post
Aberman said this approval could fast-track the cell product use for other indications relating to damaged hematological systems, including failed bone-marrow transplants, blood disorders because of prolonged chemotherapy or radiation treatment, and ...

 


Coagulation Analyzers & Reagents Market to Grow at 10.2% CAGR From 2013 to 2024: Million Insights - MarketWatch



Coagulation Analyzers & Reagents Market to Grow at 10.2% CAGR From 2013 to 2024: Million Insights 
MarketWatch
The increase in the volume of testing can be attributed to the augmented awareness among people towards lifestyle and blood disorders which is expected to further improve the diagnostic rate and preventive care management. The study covers developing ...

and more » 


Hemophilia B Treatment Future development with key players Alnylam, Amarna Therapeutics BV - Medgadget (blog)



Medgadget (blog)
 
Hemophilia B Treatment Future development with key players Alnylam, Amarna Therapeutics BV 
Medgadget (blog)
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B ? Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with ...

and more » 


Orphan Drug Designation for Treatment of Acute Radiation Syndrome - Drug Discovery & Development



Drug Discovery & Development
 
Orphan Drug Designation for Treatment of Acute Radiation Syndrome 
Drug Discovery & Development
PLX cell products release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders, and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology ...

and more » 


Rigel Pharmaceuticals, Inc. (RIGL) Receives Average Rating of ?Hold? from Analysts - StockNewsTimes



San Times
 
Rigel Pharmaceuticals, Inc. (RIGL) Receives Average Rating of ?Hold? from Analysts 
StockNewsTimes
Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and ...
$-0.15 EPS Expected for Rigel Pharmaceuticals, Inc. (RIGL); Graphic Packaging Has 0.83 Sentiment San Times

all 22 news articles » 


Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 ... - PR Newswire (press release)



Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 ... 
PR Newswire (press release)
Report covers products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Ophthalmology, Cardiovascular, Infectious Disease, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Respiratory, Genetic ...

and more » 


Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase ... - PR Newswire (press release)



Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase ... 
PR Newswire (press release)
Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders, Other Diseases, Immunology, Infectious Disease and Metabolic Disorders which include indications Acute Myelocytic Leukemia (AML, Acute ...

and more » 


Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or ... - PR Newswire (press release)



Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or ... 
PR Newswire (press release)
Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Hematological Disorders, Immunology, Male Health and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Breast Cancer, Prostate ...

and more » 


New Published Data Highlights the Potential of Pluristem's PLX Cells in Improving Cardiac Function in Diabetes - GlobeNewswire (press release)



New Published Data Highlights the Potential of Pluristem's PLX Cells in Improving Cardiac Function in Diabetes 
GlobeNewswire (press release)
PLX cell products release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders, and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology ...

and more »